专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0189520A3 DEHYDROASCORBIC ACID FORMULATIONS AND USES THEREOF 审中-公开
标题翻译：脱氢胆酸配方及其用途
公开(公告)号：WO0189520A3
公开(公告)日：2002-09-12
申请号：PCT/US0041407
申请日：2000-10-20
申请人： PROGENICS PHARM INC , OLSON WILLIAM C , ISRAEL ROBERT J , BOYD THOMAS A
发明人： OLSON WILLIAM C , ISRAEL ROBERT J , BOYD THOMAS A
IPC分类号： A61K9/08 , A61K31/375 , A61K45/06 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P9/04 , A61P9/08 , A61P9/10 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/20 , A61P25/28 , A61P27/12 , A61P29/00 , A61P31/12 , A61P35/00 , A61P39/00 , A61P39/06 , A61P43/00 , A01N1/02
CPC分类号： A61K9/0014 , A61K31/375 , A61K45/06 , A61K47/02 , A61K47/12 , A61K2300/00
摘要： The invention provides improved dehydroascorbic acid compositions and methods for treatment of medical conditions. The dehydroascorbic acid compositions are useful in the treatment of a variety of conditions which benefit from increased dehydroascorbic acid or ascorbic acid concentrations in tissues affected by the conditions.
摘要翻译：本发明提供改进的脱氢抗坏血酸组合物和治疗医学病症的方法。脱氢抗坏血酸组合物可用于治疗由受条件影响的组织中增加的脱氢抗坏血酸或抗坏血酸浓度的各种病症的治疗。

2. 发明申请

WO2007014114A3 METHODS FOR REDUCING VIRAL LOAD IN HIV-1-INFECTED PATIENTS 审中-公开
标题翻译：减少HIV-1感染患者病毒载量的方法
公开(公告)号：WO2007014114A3
公开(公告)日：2009-01-08
申请号：PCT/US2006028565
申请日：2006-07-21
申请人： PROGENICS PHARM INC , OLSON WILLIAM C , MADDON PAUL J , PEVEAR DANIEL C , ISRAEL ROBERT J , MURGA JOSE D
发明人： OLSON WILLIAM C , MADDON PAUL J , PEVEAR DANIEL C , ISRAEL ROBERT J , MURGA JOSE D
IPC分类号： A61K39/42 , A01N61/00 , C07K16/00
CPC分类号： A61K39/39 , A61K31/351 , A61K31/4178 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/551 , A61K31/7072 , A61K38/1709 , A61K38/195 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/55511 , C07K16/2866 , C07K2317/24 , C07K2317/76 , C12Q1/701 , A61K2300/00
摘要： This method provides a method for reducing HIV-I viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-I viral load- reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-I -associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-I to CCR5+CD4+ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-I comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-I to the subject's CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
摘要翻译：该方法提供了一种减少HIV-1感染的人受试者中的HIV-1病毒载量的方法，其包括以预定间隔向受试者施用有效的HIV-1病毒载量 - 减少剂量的（a）命名为PRO 140的人源化抗体，或（b）抗CCR5受体单克隆抗体。本发明还提供了一种在人受试者中抑制HIV-1相关疾病的发生或进展的方法，其抑制通过抑制受试者中HIV-1与CCR5 + CD4 +靶细胞的融合来实现。本发明还提供了用于治疗感染HIV-1的受试者的方法，其包括对受试者（a）单克隆抗体（a）与受试者的CD4 +细胞表面上的CCR5受体结合，和（ii） HIV-1对受试者的CCR5 + CD4 +细胞，和（b）非抗体CCR5受体拮抗剂，有效治疗受试者的量。

3. 发明申请

WO0164710A8 SULFATED CCR5 PEPTIDES FOR HIV-1 INFECTION 审中-公开
标题翻译：硫酸化的CCR5 HIV-1感染肽
公开(公告)号：WO0164710A8
公开(公告)日：2003-12-31
申请号：PCT/US0106699
申请日：2001-02-28
申请人： PROGENICS PHARM INC , AARON DIAMOND AIDS RES CT , DRAGIC TATJANA , OLSON WILLIAM C
发明人： DRAGIC TATJANA , OLSON WILLIAM C
IPC分类号： A61K38/00 , C07K14/715 , C07K16/28 , A61K39/00 , C07K7/00 , C07K7/06 , C07K7/08 , G01N33/53 , G01N33/566
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7158

4. 发明申请

WO2011130650A2 ANTIBODIES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED INFECTION AND DISEASE 审中-公开
标题翻译：治疗闭锁性感染相关感染和疾病的抗体
公开(公告)号：WO2011130650A2
公开(公告)日：2011-10-20
申请号：PCT/US2011032713
申请日：2011-04-15
申请人： PROGENICS PHARM INC , MA DANGSHE , NAGASHIMA KIRSTEN , KENNEDY BRIAN , DONOVAN GERALD P , KANG YUN , OLSON WILLIAM C , KUMAR SHANKAR , TSURUSHITA NAOYA , MAROZSAN ANDRE J , CUPO ALBERT
发明人： MA DANGSHE , NAGASHIMA KIRSTEN , KENNEDY BRIAN , DONOVAN GERALD P , KANG YUN , OLSON WILLIAM C , KUMAR SHANKAR , TSURUSHITA NAOYA , MAROZSAN ANDRE J , CUPO ALBERT
IPC分类号： C07K16/12 , A61K39/395 , A61P31/04 , C12N15/13
CPC分类号： C07K16/1282 , A61K39/40 , A61K45/06 , A61K2039/505 , C07K2317/14 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen- binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.
摘要翻译：本文提供了用于治疗艰难梭菌感染的试剂，组合物和治疗以及由艰难梭菌细菌感染和由这些细菌产生的肠毒素引起的相关疾病状况和病理学，例如难辨梭状芽孢杆菌相关性腹泻。特别是与艰难梭菌的毒素A和/或毒素B特异性结合并中和这些毒素的活性的抗体或其抗原结合片段; 包含这种抗体的组合物; 并提供了使用抗体和组合物的方法。

5. 发明申请

WO2004103312A3 PEPTIDES USEFUL AS HIV FUSION INHIBITORS 审中-公开
标题翻译：有效用作HIV融合抑制剂
公开(公告)号：WO2004103312A3
公开(公告)日：2005-08-11
申请号：PCT/US2004015825
申请日：2004-05-19
申请人： PROGENICS PHARM INC , OLSON WILLIAM C , SCHUELKE NORBERT , O'HARA BRYAN
发明人： OLSON WILLIAM C , SCHUELKE NORBERT , O'HARA BRYAN
IPC分类号： A61K20060101 , A61K38/00 , A61K39/21
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2740/16122
摘要： This invention provides polypeptides represented by the formula alpha-beta-gamma, which polypeptides are useful for inhibiting fusion between HIV-1 and CD4+ cells. This invention also provides related pharmaceutical compositions, nucleic acids, host-vector systems, articles of manufacture, and related methods of production, prophylaxis and therapy.
摘要翻译：本发明提供由式α-β-γ表示的多肽，该多肽可用于抑制HIV-1和CD4 +细胞之间的融合。本发明还提供相关的药物组合物，核酸，宿主 - 载体系统，制品，以及相关的生产，预防和治疗方法。

6. 发明申请

WO2007143701A8 MONOCLONAL ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS C VIRUS (HCV) OF DIVERSE GENOTYPES 审中-公开
标题翻译：中枢性嗜中性粒细胞病毒（HCV）多发性基因组的单克隆抗体
公开(公告)号：WO2007143701A8
公开(公告)日：2009-07-23
申请号：PCT/US2007070541
申请日：2007-06-06
申请人： PROGENICS PHARM INC , NAGASHIMA KIRSTEN A , OLSON WILLIAM C , MADDON PAUL J , KODURI RAJU , DONOVAN GERALD P , TSURUSHITA NAOYA , TSO J , KUMAR SHANKAR
发明人： NAGASHIMA KIRSTEN A , OLSON WILLIAM C , MADDON PAUL J , KODURI RAJU , DONOVAN GERALD P , TSURUSHITA NAOYA , TSO J , KUMAR SHANKAR
IPC分类号： C07K16/10 , A61K39/42 , A61K51/10 , C07K16/46 , C12N5/12 , C12N15/13 , C12N15/85
CPC分类号： C07K16/109 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： This invention provides potent HCV neutralizing monoclonal antibodies and portions thereof that inhibit entry of HCV into susceptible cells. The neutralizing monoclonal antibodies of the invention are broadly reactive against HCV of different genotypes, including genotypes 1 and 2. A particular monoclonal antibody, designated PA-29, does not bind soluble or independently-expressed HCV E1 and E2 envelope glycoproteins. A hybridoma cell line producing the PA-29 monoclonal antibody has been deposited under ATCC Accession No. PTA-7632. The described monoclonal antibodies, including PA-29 and humanized and chimeric forms thereof, serve as HCV antagonists for use in therapeutic and prophylactic methods of treating and preventing HIV infection of susceptible cells, in methods of blocking HCV entry into susceptible cells and in methods of diagnosis and detection of HCV in a sample of a subject and within a subject.
摘要翻译：本发明提供了有效的HCV中和单克隆抗体及其部分，其抑制HCV进入敏感细胞。本发明的中和单克隆抗体对不同基因型的HCV具有广泛的反应性，包括基因型1和2.特异性单克隆抗体（称为PA-29）不结合可溶性或独立表达的HCV E1和E2包膜糖蛋白。产生PA-29单克隆抗体的杂交瘤细胞系已经以ATCC登录号PTA-7632保藏。描述的单克隆抗体，包括PA-29及其人源化和嵌合形式，用作用于治疗和预防感染细胞的HIV感染的治疗和预防方法的HCV拮抗剂，在阻断HCV进入易感细胞的方法中诊断和检测受试者和受试者内的HCV样本。

7. 发明申请

WO2008063331A3 MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COMPLEXES, AND USES THEREOF 审中-公开
标题翻译： HIV-1分离物修饰的GP140包膜多肽，组合物，稳定的三聚体复合物及其用途
公开(公告)号：WO2008063331A3
公开(公告)日：2008-11-06
申请号：PCT/US2007022227
申请日：2007-10-17
申请人： PROGENICS PHARM INC , CORNELL RES FOUNDATION INC , DEY ANTU K , MOORE JOHN P , OLSON WILLIAM C , IYER SAI PRASAD N , KANG KENNETH , FRANTI MICHAEL
发明人： DEY ANTU K , MOORE JOHN P , OLSON WILLIAM C , IYER SAI PRASAD N , KANG KENNETH , FRANTI MICHAEL
IPC分类号： A61K39/21 , A61K39/42 , C07H21/04
CPC分类号： A61K39/21 , A61K39/00 , A61K39/12 , C07K14/005 , C12N2740/16122 , C12N2740/16134
摘要： This invention provides a modified gpl40 envelope polypeptide of an HIV-1 isolate comprising a gpl20 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof. Also provided are antibodies generated against the modified polypeptides and trimeric complexes, and methods of using the modified polypeptides, compositions and trimeric complexes.
摘要翻译：本发明提供了包含含有连续氨基酸的gp120多肽部分和含有连续氨基酸的gp41胞外域多肽部分的HIV-1分离物的经修饰的gp140包膜多肽，所述gp41胞外域多肽部分经修饰以包含氨基酸上的异亮氨酸（I）相当于氨基酸位置535的酸位; 在等同于氨基酸位置543的氨基酸位置处的谷氨酰胺（Q）丝氨酸（S）处于与氨基酸位置553等同的氨基酸位置; 位于氨基酸位置567的氨基酸位置的赖氨酸（K）; 和精氨酸（R）处于与氨基酸位置588等同的氨基酸位置，氨基酸位置参照HIV-1分离株KNH1144进行编号。本发明还提供了编码这种多肽，载体，宿主细胞，三聚体复合物及其组合物的核酸。还提供了针对修饰的多肽和三聚复合物产生的抗体，以及使用修饰的多肽，组合物和三聚复合物的方法。

8. 发明申请

WO2007143701A3 MONOCLONAL ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS C VIRUS (HCV) OF DIVERSE GENOTYPES 审中-公开
标题翻译：中枢性嗜中性粒细胞病毒（HCV）多发性基因组的单克隆抗体
公开(公告)号：WO2007143701A3
公开(公告)日：2008-09-18
申请号：PCT/US2007070541
申请日：2007-06-06
申请人： PROGENICS PHARM INC , NAGASHIMA KIRSTEN A , OLSON WILLIAM C , MADDON PAUL J , KODURI RAJU , DONOVAN GERALD P , TSURUSHITA NAOYA , TSO J , KUMAR SHANKAR
发明人： NAGASHIMA KIRSTEN A , OLSON WILLIAM C , MADDON PAUL J , KODURI RAJU , DONOVAN GERALD P , TSURUSHITA NAOYA , TSO J , KUMAR SHANKAR
IPC分类号： C07K16/10 , A61K39/42 , A61K51/10 , C07K16/46 , C12N5/12 , C12N15/13 , C12N15/85
CPC分类号： C07K16/109 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： This invention provides potent HCV neutralizing monoclonal antibodies and portions thereof that inhibit entry of HCV into susceptible cells. The neutralizing monoclonal antibodies of the invention are broadly reactive against HCV of different genotypes, including genotypes 1 and 2. A particular monoclonal antibody, designated PA-29, does not bind soluble or independently-expressed HCV E1 and E2 envelope glycoproteins. A hybridoma cell line producing the PA-29 monoclonal antibody has been deposited under ATCC Accession No. PTA-7632. The described monoclonal antibodies, including PA-29 and humanized and chimeric forms thereof, serve as HCV antagonists for use in therapeutic and prophylactic methods of treating and preventing HIV infection of susceptible cells, in methods of blocking HCV entry into susceptible cells and in methods of diagnosis and detection of HCV in a sample of a subject and within a subject.
摘要翻译：本发明提供了有效的HCV中和单克隆抗体及其部分，其抑制HCV进入敏感细胞。本发明的中和单克隆抗体对不同基因型的HCV具有广泛的反应性，包括基因型1和2.特异性单克隆抗体（称为PA-29）不结合可溶性或独立表达的HCV E1和E2包膜糖蛋白。产生PA-29单克隆抗体的杂交瘤细胞系已经以ATCC登录号PTA-7632保藏。描述的单克隆抗体，包括PA-29及其人源化和嵌合形式，用作用于治疗和预防感染细胞的HIV感染的治疗和预防方法的HCV拮抗剂，在阻断HCV进入易感细胞的方法中诊断和检测受试者和受试者内的HCV样本。

9. 发明申请

WO03087757A2 PARTICLE-BOUND HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE CLYCOPROTEINS AND RELATED COMPOSITIONS AND METHODS 审中-公开
标题翻译：颗粒人类免疫缺陷病毒包膜蛋白及相关组合物和方法
公开(公告)号：WO03087757A2
公开(公告)日：2003-10-23
申请号：PCT/US0228332
申请日：2002-09-06
申请人： PROGENICS PHARM INC , OLSON WILLIAM C , SCHULKE NORBERT , GARDNER JASON , MADDON PAUL J
发明人： OLSON WILLIAM C , SCHULKE NORBERT , GARDNER JASON , MADDON PAUL J
IPC分类号： A61K39/21 , C07K14/16 , G01N
CPC分类号： C07K14/005 , A61K31/739 , A61K38/162 , A61K38/193 , A61K38/195 , A61K38/20 , A61K39/12 , A61K39/21 , A61K2039/505 , A61K2039/545 , A61K2039/55511 , A61K2039/55522 , A61K2039/64 , C12N2740/16122 , C12N2740/16134 , A61K2300/00
摘要： This invention provides a first composition comprising a pharmaceutically acceptable particle and a stable HIV-l prefusion envelope glycoprotein trimeric complex operably affixed thereto. This invention further provides a second composition comprising (a) a pharmaceutically acceptable particle, (b) an antigen, and (c) an agent which is operably affixed to the particle and is specifically bound to the antigen, whereby the antigen is operably bound to the particle. Finally, this invention provides related nucleic acids, vectors, cells, compositions, production methods, and prophylactic and therapeutic methods.
摘要翻译：本发明提供了包含药学上可接受的颗粒和可操作地固定在其上的稳定的HIV-1预浸膜糖蛋白三聚体复合物的第一组合物。本发明进一步提供第二组合物，其包含（a）药学上可接受的颗粒，（b）抗原，和（c）可操作地固定在所述颗粒上且与所述抗原特异性结合的试剂，由此所述抗原与颗粒。最后，本发明提供了相关的核酸，载体，细胞，组合物，生产方法以及预防和治疗方法。

10. 发明申请

WO2009134401A9 METHODS OF INHIBITING INFECTION BY DIVERSE SUBTYPES OF DRUG-RESISTANT HIV-1 审中-公开
标题翻译：抑制耐药HIV-1多发性亚型感染的方法
公开(公告)号：WO2009134401A9
公开(公告)日：2010-02-11
申请号：PCT/US2009002654
申请日：2009-04-29
申请人： PROGENICS PHARM INC , OLSON WILLIAM C , KETAS THOMAS J , MAROZSAN ANDRE
发明人： OLSON WILLIAM C , KETAS THOMAS J , MAROZSAN ANDRE
IPC分类号： A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： This invention provides methods of inhibiting HIV-I infection of a susceptible cell by an HIV- 1 virus that is, or has become, resistant to one or more HIV protease inhibitors; one or more HIV reverse transcriptase inhibitors; one or more fusion inhibitors; one or more non-antibody CCR5 anatagonist inhibitors of the interaction of HIV-I gpl20 and CCR5; or one or more HIV protease inhibitors and one or more HIV reverse transcriptase inhibitors, which comprise subjecting the susceptible cell to an effective HIV-I infection inhibiting dose of a humanized antibody designated PRO 140, or of an anti-CCR5 receptor monoclonal antibody, wherein the effective HIV-I infection inhibiting dose comprises from 0.1 mg per kg to 25 mg per kg of the subject's body weight, so as to thereby inhibit the infection of the susceptible cell by HIV-I that is, or has become, resistant to one or more of the aforementioned inhibitors.
摘要翻译：本发明提供了通过已经或已经变得对一种或多种HIV蛋白酶抑制剂具有抗性的HIV-1病毒来抑制易感细胞的HIV-1感染的方法; 一种或多种HIV逆转录酶抑制剂; 一种或多种融合抑制剂; 一种或多种HIV-I gp120和CCR5相互作用的非抗体CCR5拮抗剂抑制剂; 或一种或多种HIV蛋白酶抑制剂和一种或多种HIV逆转录酶抑制剂，其包括使敏感细胞经受有效的HIV-1感染抑制剂量的命名为PRO 140的人源化抗体或抗CCR5受体单克隆抗体，其中有效的HIV-1感染抑制剂量包括每公斤体重0.1mg至25mg，从而抑制HIV-1感染易感染细胞，HIV-1已经或已经变得对一种或更多的上述抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式